Enobia Announces Positive Interim Clinical Results With ENB-0040 MONTREAL, June 11, 2009 (GLOBE NEWSWIRE) -- Enobia Pharma, an emerging biotech company focused on developing novel therapeutics for serious bone disorders, announced that results from two early-stage...

Experimental Drug Strengthens Bones in Infants With Severe Hypophosphatasia Shriners Hospitals for Children's Dr. Michael Whyte Presents First Efficacy and Safety Results of Targeted Enzyme Replacement Therapy in Patients With Rare Genetic Bone Disease ...

Enobia Pharma's ENB-0040 Receives FDA Fast Track Designation MONTREAL, May 19, 2009 (GLOBE NEWSWIRE) -- Enobia Pharma, an emerging biotech company focused on developing novel therapeutics for serious bone disorders, announced that the U.S. Food and Drug...